Chemokine receptor antagonists enhance morphine's antinociceptive effect but not respiratory depression

Aims: We have shown that chemokines injected into the periaqueductal gray region of the brain blocks opioidinduced analgesia in the rat cold-water tail flick test (CWTF). The present experiments tested whether chemokine receptor antagonists (CRAs), in combination with sub-analgesic doses of morphine, would provide maximal analgesia in the CWTF test and the mouse formalin pain assay. The effect of CRAs on respiratory depression was also evaluated. Main methods: One, two or four CRAs (AMD3100/CXCR4, maraviroc/CCR5, RS504393/CCR2 orAZD8797/ CX3CR1) were used in combination with sub-analgesic doses of morphine, all given systemically. Pain was assessed using the rat CWTF test or formalin injection into the paw of mice scored by licking. Respiration and oxygen saturation were measured in rats using a MouseOX (R) Plus - pulse oximeter. Key findings: In the CWTF test, a sub-maximal dose of morphine in combination with maraviroc alone, maraviroc plus AMD3100, or with the four chemokine receptor antagonists, produced synergistic increases in antinociception. In the formalin test, the combination of four CRAs plus a sub-maximal dose of morphine resulted in increased antinociception in both male and female mice. AMD3100 had an additive effect with morphine in both sexes. Coadministration of CRAs with morphine did not potentiate the opioid respiratory depressive effect. Significance: These results support the conclusion that combinations of CRAs can increase the potency of sub analgesic doses of morphine analgesia without increasing respiratory depression. The results support an opioid sparing strategy for alleviation of pain using reduced doses of opioids in combination with CRAs to achieve maximal analgesia.

Automated summary

The study demonstrated that combining chemokine receptor antagonists with sub-analgesic doses of morphine increased analgesic potency without exacerbating respiratory depression. This drug combination strategy allows for maximal pain relief with reduced opioid doses.